Does chronic low-grade inflammation reduce thyroid hormone signaling and lower peripheral T3?

Chronic low-grade inflammation significantly impairs thyroid hormone signaling through several distinct biological pathways. While thyroid-stimulating hormone (TSH) and thyroxine (T4) levels often remain within the standard reference range, systemic inflammation can create a "tissue-level" hypothyroid state by altering how the body processes and transports these hormones.

Mechanistic explanations

Inflammation disrupts the delicate balance of deiodinase enzymes, which are responsible for activating and deactivating thyroid hormones within cells:

• Enzymatic Reconfiguration: Pro-inflammatory cytokines, specifically interleukin-6 (IL-6) and TNF-alpha, suppress the activity of type 1 (D1) and type 2 (D2) deiodinases. These enzymes are essential for converting the precursor T4 into the active T3.
• Active Inactivation: Simultaneously, inflammation induces the expression of type 3 deiodinase (D3). This enzyme actively converts T3 and T4 into inactive forms, such as reverse T3 (rT3), further depleting the pool of active hormone available for signaling.
• Transport Bottlenecks: Inflammation also reduces the expression of critical thyroid hormone transporters, such as MCT8 and OATP1C1. In rodent models of systemic inflammation (induced by LPS), the downregulation of these transporters at the blood-brain barrier creates a bottleneck, preventing T3 and T4 from entering the central nervous system even when circulating levels are present.

Clinical and effectiveness evidence

The association between inflammatory markers and thyroid hormone profiles is consistently observed in human clinical data:

• Correlation with CRP: Multiple studies demonstrate a robust inverse relationship between high-sensitivity C-reactive protein (hs-CRP) and peripheral T3 levels. For example, in large cohorts of elderly individuals, higher levels of IL-6 and CRP are predictive of lower free T3 (FT3) and lower T3/T4 ratios, regardless of thyroid gland health.
• Non-Thyroidal Illness Syndrome (NTIS): This "low T3" state is a hallmark of NTIS, where the dose-response relationship shows that as the inflammatory burden increases, T3 levels decrease.
• Causal Evidence: Genetic studies (Mendelian randomization) suggest that chronic elevations in inflammatory markers like CRP can fundamentally alter the thyroid axis set point, potentially driving higher TSH and lower free T4 over time.

Safety and clinical implications

• Subclinical Impact: Because these changes often occur without significantly raising TSH, they may be missed by standard thyroid screening. This "low-grade" inflammation can lead to symptoms of hypothyroidism—such as fatigue and metabolic slowing—despite "normal" lab results.
• Metabolic Consequences: The reduction in intracellular T3 signaling blunts the transcription of genes responsible for mitochondrial function and oxidative metabolism in the liver and skeletal muscle, potentially contributing to metabolic syndrome.

Bottom line

Chronic low-grade inflammation reduces the biological activity of thyroid hormones by suppressing the enzymes that activate T3, inducing those that inactivate it, and downregulating the transporters that move hormones into cells. This results in reduced peripheral T3 levels and impaired signaling, which may drive metabolic symptoms even when standard thyroid tests appear normal.